India investigates Abhayrab rabies vaccine batch as substandard

By United One News · AI-generated summary of 7 outlets' reporting

Published · Updated

AI-generated summary of the coverage listed below: Indian drug regulators are investigating a batch of Abhayrab rabies vaccine that failed a potency test at the Central Drugs Laboratory. The batch, identified by number KE25012, is alleged to be misbranded or counterfeit, prompting a probe into its safety and authenticity. The manufacturer denies producing the questionable vials. The investigation follows concerns that substandard vaccines could jeopardize public health and undermine confidence in India’s immunisation programs.

Covered by 9 outlets across the spectrum: 11% left, 45% center, 44% right.

How each side framed it

Authorities probing ‘counterfeit’ rabies vaccine, says drug regulator

Left-leaning · The Hindu

India flags Abhayrab rabies vaccine batch as substandard, probes if spurious, document shows

Center · Hindustan Times

Drug regulator cracks down after misbranded Abhayrab rabies vaccine seized in Delhi

Right-leaning · India Today

Left-leaning outlets have under-covered this story. Of 9 outlets, only 1 are on the left of the spectrum.

Timeline

First reported by Hindustan Times on ; 9 articles from 7 outlets so far.

Who is covering this story

Sources

What an outlet bias classification means

Related stories